Compare Smith & Nephew plc (SNN) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Stryker Corporation — how do they compare? Smith & Nephew plc trades at $27.96 (market cap $11.62B), while Stryker Corporation trades at $277.44 (market cap $105.63B). The key difference: Stryker Corporation is far larger — about 9.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| SNN | SYK | |
|---|---|---|
Market Cap | $11.62B | $105.63B |
Sector | Health | Technology |
52-Week High | $38.53 | $388.79 |
52-Week Low | $27.80 | $275.39 |
Enterprise Value | $14.66B | $117.10B |
Dividend Yield | 2.86% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
Stryker Corporation (SYK) trades at $276.43, down 8.81% over 24 hours, reflecting bearish technical signals but strong fundamentals. The stock shows robust profitability with a 14.43% net income margin and consistent earnings beats in recent quarters. Recent developments include the launch of an FDA-cleared surgical app for Apple Vision Pro and the acquisition of ZuriMED to expand shoulder care offerings. Analyst consensus remains strongly bullish with a $372.89 price target, though ongoing securities fraud investigations pose near-term sentiment risks.
Outlook is positive long-term due to solid financial health, innovation pipeline, and institutional support, but investors face volatility from legal probes and technical bearishness. The stock's current dip may present a buying opportunity for those confident in Stryker's market position and growth trajectory, balanced against regulatory and market risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
